BGB601 (ADCT-601) is an antibody drug conjugate (ADC) composed of a humanised IgG1 antibody against human AXL that is linked to a cytotoxin. In pre-clinical experiments, BGB601 demonstrated potent and specific in vitro and in vivo anti-tumour activity in various cancer-derived models with different levels of membranous AXL. BGB601 is out-licensed to ADC Therapeutics S.a.r.l.
Selective AXL inhibitors
Footer
Get In Touch
BerGenBio ASA
Company registration number 992 219 688
Jonas Lies vei 91, 5009 Bergen, Norway
+ 47 559 61 159 (general) + 47 535 01 564 (urgent medical enquiries)